Seattle Children's Research Institute
Division of Seattle Children's Hospital & Medical Center
Latest From Seattle Children's Research Institute
Scrip caught up with several companies during the recent Cell and Gene Meeting on the Mesa, sponsored by the Alliance for Regenerative Medicine.
Industry and academic representatives shared viewpoints at Biotech Week Boston in September 2018, including what is unique about deal-making in the cell and gene field.
In back-to-back deals with AstraZeneca and Juno, Celgene has fronted nearly $1.5 billion to become a serious contender in the field of cancer immunotherapy, and is looking to lead in blood cancers.
Celgene is staking a leadership claim in immuno-oncology through a broad, 10-year collaboration with one of the leading CAR-T developers, Juno Therapeutics.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.